AbbVie Inc. (ABBV)
USD 173.02
(-1.35%)
USD 173.02
(-1.35%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 59.38 Billion USD | -6.14% |
| 2022 | 63.27 Billion USD | -17.49% |
| 2021 | 76.68 Billion USD | -10.89% |
| 2020 | 86.05 Billion USD | 28.97% |
| 2019 | 66.72 Billion USD | 65.54% |
| 2018 | 40.31 Billion USD | 7.87% |
| 2017 | 37.36 Billion USD | 1.43% |
| 2016 | 36.84 Billion USD | 16.33% |
| 2015 | 31.67 Billion USD | 110.99% |
| 2014 | 15.01 Billion USD | 1.96% |
| 2013 | 14.72 Billion USD | -6.06% |
| 2012 | 15.67 Billion USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 70.63 Billion USD | -4.55% |
| 2024 Q1 | 74 Billion USD | 24.61% |
| 2024 Q3 | 71.07 Billion USD | 0.63% |
| 2023 Q1 | 62.09 Billion USD | -1.86% |
| 2023 Q2 | 61.01 Billion USD | -1.74% |
| 2023 FY | 59.38 Billion USD | -6.14% |
| 2023 Q3 | 60.74 Billion USD | -0.44% |
| 2023 Q4 | 59.38 Billion USD | -2.24% |
| 2022 Q2 | 72.93 Billion USD | -0.74% |
| 2022 FY | 63.27 Billion USD | -17.49% |
| 2022 Q4 | 63.27 Billion USD | -9.1% |
| 2022 Q3 | 69.6 Billion USD | -4.56% |
| 2022 Q1 | 73.47 Billion USD | -4.19% |
| 2021 Q1 | 85.53 Billion USD | -0.61% |
| 2021 FY | 76.68 Billion USD | -10.89% |
| 2021 Q2 | 82.13 Billion USD | -3.97% |
| 2021 Q3 | 80.72 Billion USD | -1.73% |
| 2021 Q4 | 76.68 Billion USD | -5.0% |
| 2020 Q2 | 87.43 Billion USD | 30.41% |
| 2020 Q3 | 87.05 Billion USD | -0.43% |
| 2020 Q4 | 86.05 Billion USD | -1.15% |
| 2020 FY | 86.05 Billion USD | 28.97% |
| 2020 Q1 | 67.04 Billion USD | 0.48% |
| 2019 Q2 | 37.26 Billion USD | 0.31% |
| 2019 Q4 | 66.72 Billion USD | 73.76% |
| 2019 FY | 66.72 Billion USD | 65.54% |
| 2019 Q1 | 37.14 Billion USD | -7.85% |
| 2019 Q3 | 38.4 Billion USD | 3.06% |
| 2018 Q2 | 37.1 Billion USD | -0.48% |
| 2018 FY | 40.31 Billion USD | 7.87% |
| 2018 Q4 | 40.31 Billion USD | -0.49% |
| 2018 Q3 | 40.5 Billion USD | 9.16% |
| 2018 Q1 | 37.28 Billion USD | -0.22% |
| 2017 Q3 | 37.79 Billion USD | 1.5% |
| 2017 Q4 | 37.36 Billion USD | -1.13% |
| 2017 Q1 | 36.95 Billion USD | 0.3% |
| 2017 Q2 | 37.23 Billion USD | 0.77% |
| 2017 FY | 37.36 Billion USD | 1.43% |
| 2016 Q1 | 31.91 Billion USD | 0.76% |
| 2016 FY | 36.84 Billion USD | 16.33% |
| 2016 Q3 | 37.31 Billion USD | -1.41% |
| 2016 Q4 | 36.84 Billion USD | -1.25% |
| 2016 Q2 | 37.84 Billion USD | 18.59% |
| 2015 Q2 | 31.12 Billion USD | 103.78% |
| 2015 FY | 31.67 Billion USD | 110.99% |
| 2015 Q1 | 15.27 Billion USD | 1.75% |
| 2015 Q4 | 31.67 Billion USD | -1.42% |
| 2015 Q3 | 32.12 Billion USD | 3.23% |
| 2014 Q3 | 14.79 Billion USD | 0.35% |
| 2014 Q4 | 15.01 Billion USD | 1.48% |
| 2014 Q2 | 14.74 Billion USD | 2.33% |
| 2014 Q1 | 14.4 Billion USD | -2.15% |
| 2014 FY | 15.01 Billion USD | 1.96% |
| 2013 FY | 14.72 Billion USD | -6.06% |
| 2013 Q1 | 15.03 Billion USD | -4.05% |
| 2013 Q2 | 14.75 Billion USD | -1.86% |
| 2013 Q3 | 14.8 Billion USD | 0.35% |
| 2013 Q4 | 14.72 Billion USD | -0.58% |
| 2012 FY | 15.67 Billion USD | 0.0% |
| 2012 Q4 | 15.67 Billion USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bristol-Myers Squibb Company | 41.46 Billion USD | -43.221% |
| Bristol-Myers Squibb Company Ce | 41.46 Billion USD | -43.221% |
| Johnson & Johnson | 29.33 Billion USD | -102.458% |
| Eli Lilly and Company | 25.22 Billion USD | -135.418% |
| Merck & Co., Inc. | 36.26 Billion USD | -63.739% |
| Novartis AG | 26.34 Billion USD | -125.387% |
| Organon & Co. | 8.76 Billion USD | -577.911% |
| Pfizer Inc. | 75.04 Billion USD | 20.863% |